Thus, it seems reasonable to restart treatment as soon as the bacillary load has been reduced by anti-TB treatment, either in the case of IBD activity requiring anti-TNF or in the case of symptomatic or severe IRIS. The gene discussed is TNF; the disease is inflammatory bowel disease.